A randomised phase II study was undertaken in which patients with recurrent follicular lymphoma received either lenalidomide alone (n = 45) or lenalidomide plus rituximab (LR) (n = 46). Overall response rate was 53% for lenalidomide alone compared with 76% for LR (p = 0.029). The median time to progression was 1.1 years at the median follow up 2.5 years. Grade 3 to 4 adverse events (AEs) occurred in 58% of patients in the lenalidomide arm and 53% of patients in the LR arm. Grade 3 to 4 AEs included neutropenia, fatigue and thrombosis. Lenalidomide alone had more treatment failures with 22% of patients stopping treatment because of AEs.

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.